
First Tracks Biotherapeutics, Inc. (TRAX)
Last updated: 2026-10-27 23:59:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
First Tracks Biotherapeutics, Inc. (TRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $45.42, with a market capitalization of $1.57B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $49.91. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.57B | |
$43.33 | |
$49.91 | |
$14.72 | |
$43.48 | |
504.76K | |
844.51K | |
-- | |
$49.91 | |
$14.72 | |
-- | |
-- |
First Tracks Biotherapeutics, Inc. (TRAX) After-Hours Stock Price
First Tracks Biotherapeutics, Inc. (TRAX) is trading at $46.95 in after-hours trading as of 2026-10-27 23:31:00, up 7.98% ($3.47) from the regular-session close of $43.48.
After-hours trading shows how investors are pricing TRAX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
First Tracks Biotherapeutics, Inc. (TRAX) 7-Day Stock Price Change
Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAX) moved from $34.46 to $45.42, representing a gain of 31.80% ($10.96).
The stock traded between $33.38 and $46.05 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 929.65 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
TRAX 52-Week Price Position
Position in Range: 87.2%
TRAX is currently trading at $45.42, placing it 87.2% of the way from its 52-week low of $14.72 to its 52-week high of $49.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is First Tracks Biotherapeutics, Inc. (TRAX)?
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
First Tracks Biotherapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
How to Buy First Tracks Biotherapeutics, Inc. (TRAX) Stock on MEXC
Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is First Tracks Biotherapeutics, Inc. (TRAX) stock price today?
2.Is TRAX stock going up or down today?
3.What is TRAX pre-market price?
4.What is TRAX after-hours price?
5.Is TRAX stock trading now?
6.Where does TRAX sit relative to its 52-week high and low?
7.What sector is First Tracks Biotherapeutics, Inc. in?
8.What is First Tracks Biotherapeutics, Inc.'s market capitalization and where is it listed?
9.How is TRAX valued in terms of P/E ratio and EPS?
10.Does First Tracks Biotherapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
TRAX Stock Calculator
Estimate the value between TRAX shares and USD.
TRAX Shares to USD
1.00 TRAX shares = 45.42 USD
Calculations are estimates based on the latest available price and are for reference only.


